Education
About Us
Working with TipRanks
Follow Us
IDEAYA Biosciences (IDYA)
NASDAQ:IDYA
IDYA Analyst Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IDYA Stock 12 Month Forecast
Average Price Target
$48.40
▲(45.83% Upside)
| Highest Price Target$79.00 | Average Price Target$48.40 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$58→$62
Buy
86.80%
Upside
Reiterated
10/27/25
IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy RatingMeeng, ZLAB presented via Plenary Session updated clinical data for DLL3 topo-ADC ZL-1310, which previously read out data at ASCO 2025 and Triple Meeng 2024. Headline figures across included 60% ORR (including 6% unconfirmed; limited visibility into their eligibility for confirmaon) among all 2L SCLC paents, as well as 53% ORR (7% unconfirmed) and 68% ORR (10% unconfirmed) among 2L paents treated at 1.2 mg/kg and 1.6 mg/kg, respecvely. ZL-1310 reported 5.4 months mPFS in all paents, as well as 5.6 months mPFS in 2L paents per the abstract. We'd also note ZL-1310's early efficacy in paents with prior DLL3-targeted therapy, which included 40% ORR among N=10 paents with prior DLL3 T-cell engager therapy - this is unsurprising to us and also validang for IDE849 (and other DLL3 topo-ADCs) with respect to retaining efficacy aer AMGN's tarlatamab.
UBS
$50
Buy
50.65%
Upside
Reiterated
10/24/25
J.P. Morgan
$74→$79
Buy
138.02%
Upside
Reiterated
10/23/25
Guggenheim
$50
Buy
50.65%
Upside
Reiterated
10/22/25
Leerink Partners
$30→$33
Hold
-0.57%
Downside
Reiterated
10/21/25
Mizuho Securities
$44
Buy
32.57%
Upside
Reiterated
10/21/25
BTIG
$62
Buy
86.80%
Upside
Reiterated
10/21/25
Goldman Sachs
$27→$30
Hold
-9.61%
Downside
Reiterated
10/21/25
RBC Capital
$38→$41
Buy
23.53%
Upside
Reiterated
10/20/25
TD Cowen
―
Buy
―
Reiterated
10/20/25
Citi
$64
Buy
92.83%
Upside
Reiterated
10/19/25
IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy RatingWe not only expect IDYA’s Ph3 MUM to deliver favorable PFS by YE25 (~7 months is reasonable based on Ph1/2, >2X tebe, with control around ~3 months) but the new Ph1/2 OS data also support positive Ph3 OS.
Citizens JMP
$45
Buy
35.58%
Upside
Reiterated
10/13/25
Wells Fargo
$44
Buy
32.57%
Upside
Reiterated
09/09/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/09/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$58→$62
Buy
86.80%
Upside
Reiterated
10/27/25
IDEAYA Biosciences: Strong Clinical Data and Financial Position Justify Buy RatingMeeng, ZLAB presented via Plenary Session updated clinical data for DLL3 topo-ADC ZL-1310, which previously read out data at ASCO 2025 and Triple Meeng 2024. Headline figures across included 60% ORR (including 6% unconfirmed; limited visibility into their eligibility for confirmaon) among all 2L SCLC paents, as well as 53% ORR (7% unconfirmed) and 68% ORR (10% unconfirmed) among 2L paents treated at 1.2 mg/kg and 1.6 mg/kg, respecvely. ZL-1310 reported 5.4 months mPFS in all paents, as well as 5.6 months mPFS in 2L paents per the abstract. We'd also note ZL-1310's early efficacy in paents with prior DLL3-targeted therapy, which included 40% ORR among N=10 paents with prior DLL3 T-cell engager therapy - this is unsurprising to us and also validang for IDE849 (and other DLL3 topo-ADCs) with respect to retaining efficacy aer AMGN's tarlatamab.
UBS
$50
Buy
50.65%
Upside
Reiterated
10/24/25
J.P. Morgan
$74→$79
Buy
138.02%
Upside
Reiterated
10/23/25
Guggenheim
$50
Buy
50.65%
Upside
Reiterated
10/22/25
Leerink Partners
$30→$33
Hold
-0.57%
Downside
Reiterated
10/21/25
Mizuho Securities
$44
Buy
32.57%
Upside
Reiterated
10/21/25
BTIG
$62
Buy
86.80%
Upside
Reiterated
10/21/25
Goldman Sachs
$27→$30
Hold
-9.61%
Downside
Reiterated
10/21/25
RBC Capital
$38→$41
Buy
23.53%
Upside
Reiterated
10/20/25
TD Cowen
―
Buy
―
Reiterated
10/20/25
Citi
$64
Buy
92.83%
Upside
Reiterated
10/19/25
IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy RatingWe not only expect IDYA’s Ph3 MUM to deliver favorable PFS by YE25 (~7 months is reasonable based on Ph1/2, >2X tebe, with control around ~3 months) but the new Ph1/2 OS data also support positive Ph3 OS.
Citizens JMP
$45
Buy
35.58%
Upside
Reiterated
10/13/25
Wells Fargo
$44
Buy
32.57%
Upside
Reiterated
09/09/25
Cantor Fitzgerald
―
Buy
―
Reiterated
09/09/25
Best Analysts Covering IDEAYA Biosciences
1 Month
xxx
Success Rate
10/16 ratings generated profit
Average Return
+4.94%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +4.94% per trade.
3 Months
xxx
Success Rate
10/16 ratings generated profit
Average Return
+13.81%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +13.81% per trade.
1 Year
Success Rate
15/21 ratings generated profit
Average Return
+40.21%
reiterated a buy rating 4 days ago
Copying Charles Zhu's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +40.21% per trade.
2 Years
xxx
Success Rate
14/21 ratings generated profit
Average Return
+40.24%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +40.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IDYA Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
15
10
6
25
27
Buy
0
2
4
8
8
Hold
7
11
10
15
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
23
20
48
42
Each month's total comprises the sum of three months' worth of ratings.
IDYA Financial Forecast
IDYA Stock Forecast FAQ
What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 48.40.
What is IDYA’s upside potential, based on the analysts’ average price target?
IDEAYA Biosciences has 45.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IDYA a Buy, Sell or Hold?
IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
What is IDEAYA Biosciences’s price target?
The average price target for IDEAYA Biosciences is 48.40. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 45.83% Increase from the current price of $33.19.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 45.83% Increase from the current price of $33.19.
What do analysts say about IDEAYA Biosciences?
IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of IDYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.